3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
15
Esophageal Neoplasms
12
Colorectal Neoplasms
9
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Pancreatic Neoplasms
5
Neoplasms
4
Liver Neoplasms
4
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Melanoma
3
Carcinoma, Renal Cell
3
Liver Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Unresectable Biliary Tract Cancer
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
Irinotecan
4
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pembrolizumab
2
cobimetinib
2
Sunitinib
2
Sorafenib
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
repotrectinib
1
pralsetinib
1
osimertinib
1
lutetium Lu 177 dotatate
1
linifanib
1
guadecitabine
1
golotimod
1
genexol-PM
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Immunotherapy
×
Gastrointestinal
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled